rs1061622

[PMID 19343543] Association analysis of TNFRSF1B polymorphisms with type 2 diabetes and its related traits in North India.

[PMID 19421420] Tumor Necrosis Factor Receptor Superfamily, Member 1B Haplotypes Increase or Decrease the Risk of Inflammatory Bowel Diseases in a New Zealand Caucasian Population

[PMID 19684152] Cigarette smoking, STAT4 and TNFRSF1B polymorphisms, and systemic lupus erythematosus in a Japanese population

[PMID 21995493] TNFRSF1B +676 T>G polymorphism predicts survival of non-Small cell lung cancer patients treated with chemoradiotherapy

[PMID 15113403] Current limitations of SNP data from the public domain for studies of complex disorders: a test for ten candidate genes for obesity and osteoporosis.

[PMID 16109524] Preparation and analysis of cSNP chip on hepatocellular carcinoma-related genes.

[PMID 16380915] Replication of putative candidate-gene associations with rheumatoid arthritis in >4,000 samples from North America and Sweden: association of susceptibility with PTPN22, CTLA4, and PADI4.

[PMID 17705862] Optimization of candidate-gene SNP-genotyping by flexible oligonucleotide microarrays; analyzing variations in immune regulator genes of hay-fever samples.

[PMID 18248655] Genetic polymorphisms of tumour necrosis factor receptor superfamily 1A and 1B affect responses to infliximab in Japanese patients with Crohn’s disease.

[PMID 18385279] The tumour necrosis factor receptor superfamily member 1b 676T>G polymorphism in relation to response to infliximab and adalimumab treatment and disease severity in rheumatoid arthritis.

[PMID 18466472] Constructing gene association networks for rheumatoid arthritis using the backward genotype-trait association (BGTA) algorithm.

[PMID 18466513] Evaluating gene x gene and gene x smoking interaction in rheumatoid arthritis using candidate genes in GAW15.

[PMID 18603647] Functional genetic polymorphisms and female reproductive disorders: Part I: Polycystic ovary syndrome and ovarian response.

[PMID 18805939] Functional genetic polymorphisms and female reproductive disorders: part II–endometriosis.

[PMID 19401444] Body iron stores and glucose intolerance in premenopausal women: role of hyperandrogenism, insulin resistance, and genomic variants related to inflammation, oxidative stress, and iron metabolism.

[PMID 20007930] A functional haplotype in the 3’untranslated region of TNFRSF1B is associated with tuberculosis in two African populations.

[PMID 20018049] Evaluation of an optimal receiver operating characteristic procedure.

[PMID 20646319] TNFRSF1B A1466G genotype is predictive of clinical efficacy after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma.

[PMID 20811626] Genetic variants in inflammation-related genes are associated with radiation-induced toxicity following treatment for non-small cell lung cancer.

[PMID 22860894] Genetic polymorphisms of tumour necrosis factor receptor superfamily 1b and fas ligand are associated with clinical efficacy and/or acute severe infusion reactions to infliximab in Crohn’s disease

[PMID 23799986] Maternal tumor necrosis factor receptor 2 gene variants associated with pre-eclampsia in Tunisian women

[PMID 22921902] The methionine 196 arginine polymorphism of the TNF receptor 2 gene (TNFRSF1B) is not associated with worse outcomes in heart failure.

[PMID 23238918] Genome-wide pathway analysis of a genome-wide association study on multiple sclerosis.

[PMID 25010932] Association of TNF-α, TNFRSF1A and TNFRSF1B Gene Polymorphisms with the Risk of Sporadic Breast Cancer in Northeast Chinese Han Women

[PMID 25850964] Genetic variants within the TNFRSF1B gene and susceptibility to rheumatoid arthritis and response to anti-TNF drugs: a multicenter study

[PMID 26071216] The tumor necrosis factor receptor superfamily member 1B polymorphisms predict response to anti-TNF therapy in patients with autoimmune disease: A meta-analysis. 

Tetradecanoylphorbol Acetate	Decreases expression  , Decreases reaction	(R) , (R)
Ionomycin	Decreases expression  , Decreases reaction	(R) , (R)
Arsenic trioxide	Decreases expression	(R)
Pyrrolidine dithiocarbamic acid	Decreases expression  , Decreases reaction	(R) , (R)
Bathocuproine sulfonate	Decreases expression  , Decreases reaction	(R) , (R)

Cadmium Chloride	Decreases expression	(R)
N-Methyl-3,4-methylenedioxyamphetamine	Decreases expression	(R)
Benzo(a)pyrene	Decreases expression	(R)
Lead acetate	Decreases expression	(R)
Estrogen	Decreases expression	(R)
Neoechinulin	Decreases expression	(R)

Asbestos

Decreases expression

(R)

Nickel

Decreases expression

(R)

Ferrite	Decreases expression	(R)
Gefitinib	Decreases expression	(R)
Indole-3-carbinol	Decreases expression	(R)
Lenalidomide	Decreases expression	(R)
Sodium arsenite	Decreases expression	(R)
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	Decreases expression	(R)
Tetraarsenic tetrasulfide	Decreases expression	(R)
Acetylcysteine	Decreases expression	(R)
Air Pollutants, Occupational	Decreases expression	(R)
Aluminum	Decreases expression	(R)
Antimony Sodium Gluconate	Decreases expression	(R)
Antirheumatic Agents	Decreases expression	(R)
Arsenicals	Decreases methylation	(R)
Cuprizone	Decreases expression	(R)
Dextrans	Decreases expression	(R)
Diethylnitrosamine	Decreases expression	(R)
Hydrogen Peroxide	Decreases response to substance	(R)
Imatinib Mesylate	Decreases expression	(R)
Methyl Methanesulfonate	Decreases expression	(R)
Oxidopamine	Decreases response to substance	(R)
Progesterone	Decreases expression	(R)
Simvastatin	Decreases expression	(R)
TMC 120A	Decreases expression	(R)
Thalidomide	Decreases expression	(R)
Alfacalcidol	Decreases expression	(R)
Arsenite	Decreases expression	(R)
Chromium oxide	Decreases expression	(R)
Chromous chloride	Decreases expression	(R)
Cupric chloride	Decreases expression	(R)

 

Lipopolysaccharides	Increases expression	(R)
Pirinixic acid	Increases activity  , Increases expression	(R) , (R)

(+)-JQ1 compound

Increases expression

(R)

Bleomycin	Increases response to substance	(R)
Ketoconazole	Increases expression	(R)
Octreotide	Increases expression	(R)
SB 203580	Increases expression	(R)
Vehicle Emissions	Increases expression	(R)
Procyanidin B3	Increases expression	(R)
Terameprocol	Increases expression	(R)
Carbon Monoxide	Increases expression	(R)
Magnetite Nanoparticles	Increases expression	(R)
Melatonin	Increases response to substance	(R)
Mycophenolic Acid	Increases expression	(R)
Nitrogen Dioxide	Increases expression	(R)
C646 compound	Increases expression	(R)
Sanguinarine	Increases expression	(R)
Oleanolic Acid	Increases expression	(R)
Azacitidine	Increases expression	(R)
PLX4032	Increases expression	(R)
Pentachlorophenol	Increases expression	(R)
Polycyclic Hydrocarbons, Aromatic	Increases expression	(R)
Propylthiouracil	Increases expression	(R)
Quercetin	Increases expression	(R)
Zoledronic acid	Increases expression	(R)
3,3-dimethylallyl pyrophosphate	Increases expression	(R)
Succimer	Increases expression	(R)
Titanium dioxide	Increases expression	(R)
WR 1065	Increases activity	(R)
Zymosan	Increases expression	(R)
Abrine	Increases expression	(R)
Aloe emodin	Increases expression	(R)
Bisphenol A	Increases expression	(R)
Brevianamide A	Increases expression	(R)
Butylphen	Increases expression	(R)
Fusarenon-X	Increases expression	(R)
Hopane	Increases expression	(R)
N-butoxyethanol	Increases expression	(R)
Nickel sulfate	Increases expression	(R)
Pantogab	Increases expression	(R)
2-(1’H-indolo-3′-carbonyl)thiazole-4-carboxylic acid methyl ester	Increases expression	(R)
Vinclozolin	Increases expression	(R)
Dust	Increases expression	(R)
Environmental Pollutants	Increases expression	(R)
Ethinyl Estradiol	Increases expression	(R)
Dextran Sulfate	Increases expression	(R)
Resveratrol	Increases response to substance	(R)
Lead	Increases expression	(R)

Ozone

Decreases reaction

(R)